阿片类药物所致胃肠道症状治疗的新进展。
New developments in the treatment of opioid-induced gastrointestinal symptoms.
作者信息
Pannemans Jasper, Vanuytsel Tim, Tack Jan
机构信息
Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven University, Leuven, Belgium.
出版信息
United European Gastroenterol J. 2018 Oct;6(8):1126-1135. doi: 10.1177/2050640618796748. Epub 2018 Aug 27.
Abstract
Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation (OIC), a highly prevalent adverse effect of opioid use, has a major impact on patients' quality of life. Thanks to the introduction of new drugs for chronic constipation, which can also be used in OIC, and the development of peripherally acting mu-opioid receptor blockers, specifically for use in OIC, therapeutic options have seen major development. This review summarises current and emerging treatment options for OIC based on an extensive bibliographical search. Efficacy data for laxatives, lubiprostone, prucalopride, linaclotide, oxycodone/naloxone combinations, methylnaltrexone, alvimopan, naloxegol, naldemedine, axelopran, and bevenopran in OIC are summarised.
摘要
慢性疼痛影响着全球很大一部分人口，导致阿片类药物使用量增加。阿片类药物引起的便秘（OIC）是阿片类药物使用中一种非常普遍的不良反应，对患者的生活质量有重大影响。由于可用于慢性便秘且也可用于OIC的新药的推出，以及专门用于OIC的外周作用μ-阿片受体阻滞剂的开发，治疗选择有了重大进展。本综述基于广泛的文献检索总结了OIC目前和新出现的治疗选择。总结了泻药、鲁比前列酮、普芦卡必利、利那洛肽、羟考酮/纳洛酮组合、甲基纳曲酮、阿洛司琼、纳洛戈、纳地美定、阿克洛普仑和贝韦普仑在OIC中的疗效数据。
相似文献
1
New developments in the treatment of opioid-induced gastrointestinal symptoms.阿片类药物所致胃肠道症状治疗的新进展。
United European Gastroenterol J. 2018 Oct;6(8):1126-1135. doi: 10.1177/2050640618796748. Epub 2018 Aug 27.
2
Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.阿片类药物引起的便秘的治疗效果：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1569-1584.e2. doi: 10.1016/j.cgh.2018.01.021. Epub 2018 Jan 31.
3
Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.非癌性疼痛中阿片类药物所致便秘药物治疗的循证综述
Ann Pharmacother. 2018 Apr;52(4):370-379. doi: 10.1177/1060028017739637. Epub 2017 Nov 2.
4
Emerging therapies for opioid-induced constipation: what can we expect?阿片类药物引起的便秘的新兴治疗方法：我们能期待什么？
Expert Opin Pharmacother. 2024 Sep;25(13):1729-1738. doi: 10.1080/14656566.2024.2407013. Epub 2024 Sep 23.
5
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.外周作用的μ-阿片受体拮抗剂作为慢性阿片类药物治疗的非癌痛患者便秘的治疗选择。
Patient Prefer Adherence. 2017 Jan 17;11:107-119. doi: 10.2147/PPA.S78042. eCollection 2017.
6
Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.阿片类药物引起的便秘和肠道功能障碍的管理：意大利多学科专家组的专家意见。
Adv Ther. 2021 Jul;38(7):3589-3621. doi: 10.1007/s12325-021-01766-y. Epub 2021 Jun 4.
7
Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.对于慢性重度疼痛且泻药难治性便秘的患者，与缓释羟考酮相比，使用缓释羟考酮/纳洛酮治疗可改善疼痛缓解情况及阿片类药物所致便秘。
Clin Ther. 2015 Apr 1;37(4):784-92. doi: 10.1016/j.clinthera.2015.02.010. Epub 2015 Mar 7.
8
Management of Opioid-induced Constipation in Older Adults.老年人阿片类药物引起的便秘的管理
J Clin Gastroenterol. 2023 Jan 1;57(1):39-47. doi: 10.1097/MCG.0000000000001801.
9
Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain.慢性非癌痛患者阿片类药物相关性便秘的临床概述及处理注意事项。
Clin J Pain. 2019 Feb;35(2):174-188. doi: 10.1097/AJP.0000000000000662.
10
Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.慢性非癌性疼痛患者阿片类药物所致肠道功能障碍的新型口服疗法
Pharmacotherapy. 2016 Mar;36(3):287-99. doi: 10.1002/phar.1711. Epub 2016 Mar 6.
引用本文的文献
1
Prognosis of liver transplantation: Does postoperative ileus matter?肝移植预后：术后肠梗阻是否重要？
BMC Gastroenterol. 2021 Nov 25;21(1):444. doi: 10.1186/s12876-021-02026-7.
2
Magnesium Oxide in Constipation.氧化镁治疗便秘。
Nutrients. 2021 Jan 28;13(2):421. doi: 10.3390/nu13020421.
3
Medications Development for Treatment of Opioid Use Disorder.用于治疗阿片类物质使用障碍的药物研发
Cold Spring Harb Perspect Med. 2021 Jan 4;11(1):a039263. doi: 10.1101/cshperspect.a039263.
4
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.肿瘤患者的阿片类药物相关性便秘：新的管理策略。
Curr Treat Options Oncol. 2019 Dec 19;20(12):91. doi: 10.1007/s11864-019-0686-6.
5
making the next step.迈出下一步。
United European Gastroenterol J. 2019 Feb;7(1):5-6. doi: 10.1177/2050640618822884. Epub 2019 Jan 30.
本文引用的文献
1
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.长期使用纳洛美丁治疗慢性非癌痛患者阿片类药物引起的便秘：一项随机、双盲、安慰剂对照的 3 期研究。
Pain. 2018 May;159(5):987-994. doi: 10.1097/j.pain.0000000000001174.
2
Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.鲁比前列酮治疗阿片类药物诱导性便秘的疗效和安全性：3 期研究结果及合并使用美沙酮对临床结局影响的汇总分析。
Pain Med. 2018 Jun 1;19(6):1184-1194. doi: 10.1093/pm/pnx156.
3
Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.纳洛美丁与安慰剂治疗阿片类药物引起的便秘（COMPOSE-1 和 COMPOSE-2）：两项多中心、3 期、双盲、随机、平行组试验。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564. doi: 10.1016/S2468-1253(17)30105-X. Epub 2017 May 30.
4
Management of chronic pain using complementary and integrative medicine.采用补充和整合医学方法管理慢性疼痛。
BMJ. 2017 Apr 24;357:j1284. doi: 10.1136/bmj.j1284.
5
Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.阿片类药物引起的便秘和肠道功能障碍：临床指南。
Pain Med. 2017 Oct 1;18(10):1837-1863. doi: 10.1093/pm/pnw255.
6
Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.随机、双盲临床试验：口服美沙酮治疗慢性非癌痛患者阿片类药物诱导性便秘
Pain Pract. 2017 Jul;17(6):820-828. doi: 10.1111/papr.12535. Epub 2017 Feb 10.
7
Bowel Disorders.肠道疾病
Gastroenterology. 2016 Feb 18. doi: 10.1053/j.gastro.2016.02.031.
8
Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response.纳洛酮在阿片类药物诱导的便秘和泻药反应不足的患者中的疗效和安全性。
United European Gastroenterol J. 2015 Oct;3(5):471-80. doi: 10.1177/2050640615604543.
9
Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain.鲁比前列酮用于慢性非癌性疼痛患者阿片类药物所致便秘的长期安全性和有效性
Pain Pract. 2016 Nov;16(8):985-993. doi: 10.1111/papr.12347. Epub 2015 Aug 29.
10
A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.鲁比前列酮治疗慢性非癌性疼痛中阿片类药物所致便秘的随机、安慰剂对照试验。
Am J Gastroenterol. 2015 May;110(5):725-32. doi: 10.1038/ajg.2015.106. Epub 2015 Apr 28.
Zotero 插件